Advertisement
Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. (HALO) Stock Overview

Explore Halozyme Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

HALO●NASDAQ
HealthcareBiotechnology
$71.60
$1.78(2.55%)
U.S. Market opens in 14h 50m
Advertisement

Halozyme Therapeutics, Inc. (HALO)

Meyka AI Score

Z

Key Financials

Market Cap8.5B
P/E Ratio24.28
EPS (TTM)$2.85
ROE1.26%
Fundamental Analysis

AI Price Forecasts

1 Month$50.91
3 Months$75.22
1 Year Target$80.84

HALO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Halozyme Therapeutics, Inc. (HALO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of A, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 61.68, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $80.84.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 24.28 and a market capitalization of 8.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
2.55%
5-Day Change
4.92%
1-Month Change
10.89%
3-Month Change
2.26%
6-Month Change
13.74%
Year-to-Date (YTD) Change
6.39%
1-Year Change
32.96%
3-Year Change
116.58%
5-Year Change
81.40%
All-Time (Max) Change
1584.71%

Contact Information

https://www.halozyme.com
858 794 8889
11388 Sorrento Valley Road, San Diego, CA, 92121

Company Facts

350 Employees
IPO DateMar 16, 2004
CountryUS
Actively Trading

Frequently Asked Questions